Maj-Britt Kaltoft
Corporate Officer/Principal presso Statens Serum Institute
Posizioni attive di Maj-Britt Kaltoft
Società | Posizione | Inizio | Fine |
---|---|---|---|
Statens Serum Institute | Corporate Officer/Principal | 01/01/2017 | - |
Storia della carriera di Maj-Britt Kaltoft
Precedenti posizioni note di Maj-Britt Kaltoft
Società | Posizione | Inizio | Fine |
---|---|---|---|
SANUWAVE HEALTH, INC. | Direttore/Membro del Consiglio | 16/06/2017 | 28/06/2021 |
Independent Dir/Board Member | 16/06/2017 | 28/06/2021 | |
NOVO NORDISK A/S | Corporate Officer/Principal | 01/01/2011 | 01/01/2016 |
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Direttore operativo | 01/11/2010 | 10/06/2011 |
Nycomed Hellas SA | Direttore/Membro del Consiglio | 01/01/2007 | 01/01/2007 |
H. LUNDBECK A/S | Corporate Officer/Principal | 01/01/2003 | 01/01/2003 |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - | - |
EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Direttore operativo | 13/06/2011 | - |
Formazione di Maj-Britt Kaltoft
University of Copenhagen | Doctorate Degree |
Seattle University | Graduate Degree |
Statistiche
Distribuzione geografica
Danimarca | 6 |
Stati Uniti | 4 |
Grecia | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Chief Operating Officer | 2 |
Graduate Degree | 2 |
Settori
Health Technology | 6 |
Consumer Services | 4 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
NOVO NORDISK A/S | Health Technology |
H. LUNDBECK A/S | Health Technology |
SANUWAVE HEALTH, INC. | Health Technology |
Aziende private | 4 |
---|---|
EffRx, Inc.
EffRx, Inc. Pharmaceuticals: MajorHealth Technology EffRx Inc. is an innovative company that exploits drug delivery technologies to improve the efficacy and tolerability of existing approved compounds with a focus on drugs, with high commercial potential and once developed partner these products with established pharmaceutical companies. Their goal is to become a global provider of products, based on alternative drug delivery technologies for both the prescription and OTC markets, by applying their technologies to well established proven compounds and developing reformulated products with reduced gastrointestinal side effects, better absorption and faster onset of action. Thereby generating better products for patients in a cost effective manner. The primary focus and the leading project is to introduce EX101 (a proprietary effervescent alendronate) in markets worldwide, capitalizing on the unique intellectual property position of the combined EffRx patents and the patents exclusively licensed from Merck & Co. | Health Technology |
Nycomed Hellas SA | |
EffRx Pharmaceuticals SA
EffRx Pharmaceuticals SA Pharmaceuticals: OtherHealth Technology EffRx Pharmaceuticals SA manufactures and distributes specialty pharmaceutical products. The firm's focus areas include metabolic bone disease, oncology supportive care, pediatric medication, and medical support to companies in life cycle management. It also engages in licensing agreements and distribution and commercialization partnerships. The company was founded by Christer Ros?n in 1998 and is headquartered in Freienbach, Switzerland. | Health Technology |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
- Borsa valori
- Insiders
- Maj-Britt Kaltoft
- Esperienza